Sironax will present two posters at ObesityWeek 2026 on SIR4156, an orally active allosteric NAMPT activator developed for obesity and metabolic dysfunction. Preclinical data in diet-induced obese mice reportedly show weight reduction with preferential fat loss, preservation of lean mass, reduced muscle atrophy and improved physical performance, alongside a weight-of-evidence carcinogenicity risk assessment. The compound is in a Phase 2 trial (FORGE-LM) as monotherapy and in combination with incretins.
Key Points
- NAMPT activator SIR4156 lowered weight in diet-induced obese mice
- Preclinical data indicate fat loss with lean-mass preservation
- Phase 2 FORGE-LM trial enrolling; incretin combination under evaluation
Longevity Analysis
Muscle loss is the principal liability of current pharmacologic weight reduction, and preserving contractile tissue determines whether fat loss translates into durable metabolic and functional benefit. Targeting NAMPT places the intervention upstream at NAD+ salvage, the rate-limiting step for cellular fuel handling and repair capacity, rather than at appetite signaling alone. The inclusion of a carcinogenicity risk assessment is appropriate given that enhancing NAD+ availability also supports proliferative tissue, and that question will govern how such agents are weighed for long-term use.
Original published by LT Wire.